APO-Pemetrexed pemetrexed 500 mg (as disodium) powder for injection vial

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

pemetrexed disodium hemipentahydrate, Quantity: 604 mg (Equivalent: pemetrexed, Qty 500 mg)

Verfügbar ab:

Arrotex Pharmaceuticals Pty Ltd

INN (Internationale Bezeichnung):

pemetrexed disodium hemipentahydrate

Darreichungsform:

Injection, powder for

Zusammensetzung:

Excipient Ingredients: sodium hydroxide; hydrochloric acid; mannitol

Verabreichungsweg:

Intravenous Infusion

Einheiten im Paket:

1

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Produktbesonderheiten:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2014-09-04